Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

International Journal of Infectious Diseases

Volumn 62, Issue , 2017, Pages 39-43

  Alatoom, Adnan ^a   Elsayed, Hashim ^a   Lawlor, Karen ^a   AbdelWareth, Laila ^a   El Lababidi, Rania ^a   Cardona, Lysettee ^a   Mooty, Mohammad ^a   Bonilla, Maria Fernanda ^a   Nusair, Ahmad ^a   Mirza, Imran ^a  

^a HEART AND VASCULAR INSTITUTE   (United Arab Emirates)

Author keywords

carbapenem resistant Enterobacteriaceae (CRE); Ceftazidime avibactam; Ceftolozane tazobactam; Gram negative bacteria; Multidrug resistance

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CITROBACTER FREUNDII; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; UNITED ARAB EMIRATES;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEFTAZIDIME; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; UNITED ARAB EMIRATES;

EID: 85026368398     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2017.06.007     Document Type: Article

References (16)

1. Aly, M., Balkhy, H.H., The prevalence of antimicrobial resistance in clinical isolates from Gulf Corporation Council countries. Antimicrob Resist Infect Control, 1(1), 2012, 26.
2. Anon, Zerbaxa™ (ceftolozane sulfate; tazobactam sodium) [package insert]. 2015, Cubist Pharmaceuticals LLC, Lexington, MA.
3. Anon, Avycaz™ (avibactam sodium; ceftazidime) [package insert]. 2015, GlaxoSmithKling, Verona, Italy.
4. Farrell, D.J., Flamm, R.K., Sader, H.S., Jones, R.N., Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012). Antimicrob Agents Chemother 57 (2013), 6305–6310.
5. Flamm, R.K., Farrell, D.J., Sader, H.S., Jones, R.N., Ceftazidime/avibactam activity tested against gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother 69 (2014), 1589–1598.
6. Goodlet, K.J., Nicolau, D.P., Nailor, M.D., Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections. Ther Clin Risk Manag 12 (2016), 1811–1826.
7. Lagace-Wiens, P., Walkty, A., Karlowsky, J.A., Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 9 (2014), 13–25.
8. Liscio, J.L., Mahoney, M.V., Hirsch, E.B., Ceftolozane/tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents 46 (2015), 266–271.
9. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:3 (2012), 268–281.
10. Pitart, C., Marco, F., Keating, T.A., Nichols, W.W., Vila, J., Activity of Ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 59 (2015), 3059–3065.
11. Sader, H.S., Farrell, D.J., Castanheira, M., Flamm, R.K., Jones, R.N., Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 69 (2014), 2713–2722.
12. Sader, H.S., Castanheira, M., Mendes, R.E., Flamm, R.K., Farrell, D.J., Jones, R.N., Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centersin 2012 and 2013. Antimicrob Agents Chemother 59 (2015), 3656–3659.
13. Sonnevend, A., Al Baloushi, A., Ghazawi, A., Hashmey, R., Girgis, S., Hamadeh, M.B., Al Haj, M., Pal, T., Emergence and spread of NDM-1 producer Enterobacteriaceae with contribution of IncX3 plasmids in the United Arab Emirates. J Med Microbiol 62 (2013), 1044–1050.
14. Yezli, S., Shibl, A.M., Memish, Z.A., The molecular basis of β-lactamase production in Gram-negative bacteria from Saudi Arabia. J Med Microbiol 64:2 (2015), 127–136.
15. Zahedi-bialvaei, A., Samadi-kafil, H., Ebrahimzadeh-leylabadlo, H., Asgharzadeh, M., Aghazadeh, M., Dissemination of carbapenemases producing Gram negative bacteria in the Middle East. Iran J Microbiol 7:5 (2015), 226–246.
16. Zowawi, H.M., Balkhy, H.H., Walsh, T.R., Paterson, D.L., β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev 26 (2013), 361–380.